US EditionPublished • loading... • Updated
Cell and Gene Therapy Investment Strategy Pivots as Funding Dries up - Pharmaceutical Technology
Summary by Pharmaceutical-technology.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Cell and gene therapy investments shift as budgets tighten and big pharma recalibrates towards strategic acquisitions, says GlobalData
The cell and gene therapy (CGT) sector is undergoing a transition as companies navigate a more selective and strategy-driven funding landscape, according to an analysis by the Pharma Strategic Intelligence team at GlobalData, a leading data and analytics company. While venture capital (VC) investment in CGTs has declined in recent years after a peak during the COVID-19 pandemic, mirroring broader industry trends, CGT-focused deals within the bio…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium